bric, not a bright idea for you to make a comment establishing that you are a moron. Do you really think a company, particularly small cap even KNOWS its earnings at least that it can publicly report 7 days after close? Seagate (STX) an 8 billion market cap company pre-announced their revenue after hours, a beat, and of course no mention of earnings because its too soon after quarter end. No responsible company would do that except for companies like OSIR that appear to make up their numbers and even new auditors ,Big 4 auditors to boot, after 6 months of review can't figure out what the heck tiny OSIR did. LOL!
How's your short doing at $6, $5 etc? Remember, you told everyone you were shorting it down to $3. Wait, let me guess, you got out just in time and only shorted it when it was above $8. LOL!
Christian/Candy gets more desperate with his his drivel as the stock goes higher. I suspect by the end of this year his desperation will be at all time highs as his short starts to strangle his balls.
This is funny. I mean, this isn't Apple or a multinational organization. It's a two bit $90 million revenue company. How long can it take to do the financial statements? Heck, you could do them on Quickbooks. And a Big 4 accounting firm can't get to the bottom of this yet? Gotta wonder what they are finding????
lean, Not sure what you are expecting in terms of an update related to Stifel's work. They were hired to find a buyer and sell the company and that isn't something management will discuss so the only update we will get on that will be a PR announcing a sale
Funny. Jason was actually spot on his OSIR call was he not? Anyone who paid attention to him made a bundle. He's got a good reputation and good bio. from 2013 announcement. Those are colleges by the way for you OSIR high school grad types.
Jason Wittes joins the firm’s Healthcare Group as a Senior Analyst covering the Medical Technology and Supply industry. Mr. Wittes has over 15 years of experience covering the sector as a Senior Analyst at Morgan Stanley, Leerink & Swann and Caris. Mr. Wittes has been ranked by both Institutional Investor and Greenwich Associates. Mr. Wittes earned an M.B.A. from New York University’s Stern School of Business and a B.S. in Chemistry from Carnegie Mellon University.
mm, it is available on the website for one thing and also, analysts have their own contacts in industry. If you are an analyst in the healthcare sector, you have developed industry contacts over the years so a lot of what they do is call contacts informally: "hey, what do you see going on at your hospital". "Hey, what are you seeing in terms of Grafix uptake with the turmoil at the company"? SO a lot of what analyst get is not data they can give you
mm, but if you will refresh me on Grafix contract numbers I will try to check. I have V797P4478B but thought there might be another and this one seems low.
Ozark why is OSIR's market share dropping even at the VA. Looks like Jason's checks agree within that OSIR's VA share continued to drop
Of course, no one cares about a non study..that is why OSIR continues to lose market share including at the VA
see note I just posted which confirms the numbers I have pulled..a declining share for OSIR
MDXG and OSIR Field Checks Investment Summary
1. MDXG (MDXG $7.11, Buy) continues to be confident into 2Q, however, but looks to the second half for acceleration—we are projecting 2Q14 revenue of 23% growth to $56.1 million versus consensus of $56.3 million/EPS of $0.07 in line with consensus.
2. Surgical uptake remains key to second half acceleration, and while there is no specific reimbursement for amniotic tissue, there is a growing opportunity with procedures with healthy DRG reimbursement.
3. Our checks with sports medicine and orthopedic foot and ankle docs point to growing interest in using amniotic tissue especially for tendon repair procedures. Checks with GI surgeons also show growing interest.
4. OSIR (OSIR $5.15, Sell) continues to be in disarray, due to significant management and resulting sales force turnover. Competitors are beginning to capitalize and take share, notably with Veteran Affairs Hospitals.
Valuation / Target Price
We are applying a current multiple of 4-5x EV/Sales to our 2017 estimate to get a $12 target price.
Market. Go ahead and verify if you want. Were't you going to verify my MDXG numbers with the contract numbers I provided? I think you were on your cell and you said you were going to check when you were on your computer? Or was that another OSIT pumper? I don't have to believe anything. I am looking at the spreadsheets I downloaded
Sorry baby, numbers have been posted. Still 3:1 and ratio not shrinking
We are suspending our Investment Rating and 12-month Price Target on Osiris until we have greater clarity on the company's outstanding accounting issues and SEC/Justice Department investigations. Osiris has yet to restate 2014 annual and 2015 quarterly results, and failed to report 4Q:15/2015 and 1Q:16 results. NASDAQ has granted the company 180 days or until September 12 to regain compliance. At this point we are not changing our revenue forecast of $110M this year and $125M in 2017. Osiris ended 3Q:15 with cash and securities of $43.3M
correct peterpuck. MM says the tide is turning. Based on what? Hasn't the ratio at the VA been 3:1 for a very long time?? How do the latest numbers show the tide is turning? OSIR has a lot bigger issues to deal with than VA sales...like trying to stay afloat.